Andrew
Calica

Represented a global chemical company in personal injury, medical monitoring, property damage, water district, customer class, and natural resource damages cases.

Secured trial victory for global bank on claim of breach of the implied covenant of good faith and fair dealing in connection with a revolving credit agreement.

Obtained dismissal of Commodity Exchange Act claims against global bank in LIBOR class action.

Represented global pharmaceutical company in connection with N.Y. False Claims Act claim by New York Attorney General.

Represented brand name pharmaceutical companies as national counsel supervising cases involving 8,000 product liability plaintiffs.

Bell v. Pfizer (8th Cir. 2013); Fullington v. Pfizer (8th Cir. 2013); Strayhorn v. Wyeth (6th Cir. 2013); Eckhardt v. Qualitest (5th Cir. 2014); Huck v. Trimark (Iowa 2014); Smith v. Wyeth (6th Cir. 2011); Mensing v. Wyeth (8th Cir. 2009). Obtained dismissal for brand name pharmaceutical company in failure to warn cases involving ingestion of generic pharmaceuticals.

Assisted a multi-national pharmaceutical company in a licensing dispute before the ICC International Court of Arbitration.

Represented an owner participant in a contested bankruptcy proceeding concerning tax indemnity claims arising out of the purchase of aircraft.

Represented a global pharmaceutical company in connection with an internal investigation arising out of a clinical trial.

Defended a leading broker dealer against $500 million claims that it colluded to inflate the valuation of mortgage-backed securities held by a hedge fund customer.

Defended a global bank in a commercial arbitration that involved an accounting dispute with the bank’s former subsidiary.